drugset / Trial / NCT01573702
Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR)
Phase 2
Completed
32 enrolled
UNC Lineberger Comprehensive Cancer Center
Astellas Pharma Global Development, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
\- Progression free survival after locally ablative therapy and erlotinib in EGFR patients progressed after EGFR-TKI therapy
Timeline
- Start
- 2012-12-11
- Primary completion
- 2019-03-15
- Completion
- 2019-03-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erlotinib | Small molecule | 150 mg | — |